BRCA2 and neoplasm: Mucinous tumours provided supporting evidence against BRCA2 variant pathogenicity in individuals diagnosed both before the age of 50 (LR: 0.36 (95% CI: 0.16–0.80), supporting evidence) and after the age of 50 (LR: 0.42 (95% CI: 0.21–0.87), supporting evidence).